Home / Pharma News

Pharma News

Drawing score lines on pills to delay generics

Brand-name drugmakers have come up with numerous ways in the past to delay generics from entering the market. These can include making slight changes to the doses, introducing a paediatric form, pay-for-delay deals or even buying the company that makes the active pharmaceutical ingredient. The latest novel tactic from an originator drug company, however, is coming simply in the form of a line.

Aurobindo forms generics joint venture with Russia’s Diod

India-based Aurobindo Pharma (Aurobindo) announced on 7 September 2011 that it had formed a joint venture with Russian company Ojsc Diod (Diod) to manufacture and sell pharmaceutical products in Belarus, Kazakhstan and Russia.

Pfizer and US pharmacies fight counterfeit medicines

Pfizer and the US National Association of Boards of Pharmacy (NABP) announced on 29 September 2011 that they have launched a new effort to draw attention to the risks associated with counterfeit drugs and to help patients learn how to buy medicines online safely.

Sun Pharma’s US operations partially on track

Sun Pharma announced on 19 September 2011 that its US arm has resolved issues raised by the country’s health regulator regarding violation of manufacturing standards.

Authorised generics implicated in pay-to-delay deals

A US Federal Trade Commission (FTC) report has found that authorised generics may reduce generics competition. The report also shows that some originator companies may have used agreements not to launch an authorised generic drug as a way to compensate would-be generic competitors for delaying entry into the market.

Eli Lilly in deal with Turkish generics company

American drugmaker Eli Lilly is in talks to form a partnership with, and potentially invest in, Turkish generic drugs company Mustafa Nevzat İlaç Sanayii A.Ş. (MN Pharmaceuticals), according to a Wall Street Journal report from 2 September 2011.

Medivir subsidiary BioPhausia sells generics business

Sweden-based Medivir announced on 25 August 2011 that its subsidiary BioPhausia had reached an agreement to sell its generics business (BMM Pharma) to Bluefish Pharmaceuticals (Bluefish) for SEK 26 million plus the value of inventories, some SEK 12 million. The staff of BMM Pharma will not be transferred in the acquisition.

GaBI Online launches its country focus section

- Provides Easy to Find Country Specific Information -

FIRST IN THE SPOTLIGHT – BELGIUM, THE NETHERLANDS AND UK

Generics of antibiotic Levaquin approved by FDA

The FDA has approved the first generic versions of Johnson and Johnson’s (J&J) blockbuster antibiotic Levaquin (levofloxacin), used to treat bacterial infections of the skin, sinuses, kidneys, bladder, and prostate caused by specific germs.

Record high drug shortages in the US

In 2010, there were 178 drugs that experienced shortages in the US, see Figure 1. This is a record high level and regulators blame quality and manufacturing problems for the crisis. Worse still, many of the drugs identified in 2010 remain unavailable or in short supply in 2011.

Generics News Research General

more

Biosimilars News Research General

more